This competing renewal proposes to define the recommended phase II dose and toxicities of new antineoplastic agents, including approaches to amelioration of such toxicity; to define the pharmacokinetics, pharmacodynamics, and pharmacogenetics of new antineoplastic agents; to develop new combinations that enhance the therapeutic index and/or oral bioavailability of new or established agents; and to develop and implement novel methodological approaches to phase I studies. This proposal includes three ongoing studies and five new studies. The proposed new studies build on the applicants' experience and accomplishments with irinotecan and O6-benzylguanine. In addition, three new studies are proposed involving tyrosine kinase inhibitors (e.g. 0SI-774, imatinib). Most of the studies will evaluate novel therapies in patients with advanced solid tumors. In addition, one ongoing and one planned study focus on patients with advanced hematologic malignancies. All of the proposed studies will include pharmacokinetic or correlative components. The latter will include pharmacodynamic studies of tumor and normal tissue evaluating signal transduction endpoints, as well as pharmacogenetic studies. The proposed pharmacogenetic studies will be performed in collaboration with the Pharmacogenetics of Anticancer Agents Research (PAAR) Group, chaired by the Principal Investigator. The PAAR Group is part of a larger NIH Pharmacogenetics Research Network, administered through NIGMS. This application also includes a proposal for the creation of an Early Clinical Trials Network to facilitate inter-institutional collaborations involving NCI-sponsored early clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Ivy, S Percy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Geeleher, Paul; Loboda, Andrey; Lenkala, Divya et al. (2015) Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst 107:
Maitland, Michael L; Xu, Chun-Fang; Cheng, Yu-Ching et al. (2015) Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res 21:365-72
O'Donnell, Peter H; Karovic, Sanja; Karrison, Theodore G et al. (2015) Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res 21:5092-9
Odenike, Olatoyosi; Halpern, Anna; Godley, Lucy A et al. (2015) A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs 33:371-9
Paller, Channing J; Bradbury, Penelope A; Ivy, S Percy et al. (2014) Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res 20:4210-7
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Karovic, S; Wen, Y; Karrison, T G et al. (2014) Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther 96:27-35
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Sharma, Manish R; Karrison, Theodore G; Kell, Bethany et al. (2013) Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res 19:3059-67
O'Donnell, Peter H; Undevia, Samir D; Stadler, Walter M et al. (2012) A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 30:604-10

Showing the most recent 10 out of 37 publications